Index of /wp-content/uploads/2014/07/
| Name | Last Modified | Size |
|---|---|---|
 Parent Directory | ||
 Alemtuzumab-Summary.pdf | 2023-03-09 11:31 | 140k |
| Ambrisentan-Volibris-summary.pdf | 2023-03-09 11:31 | 90k |
| Dimethyl-Fumarate-Tecfidera-2015.pdf | 2023-03-09 11:31 | 146k |
| Dimethyl-Fumarate-Tecfidera-20151.pdf | 2023-03-09 11:31 | 146k |
| FINAL-NCPE-Summary.pdf | 2023-03-09 11:31 | 137k |
| NCPE-Summary.pdf | 2023-03-09 11:31 | 140k |
| NCPE-Summary1.pdf | 2023-03-09 11:31 | 140k |
| NCPE-Summary2.pdf | 2023-03-09 11:31 | 140k |
| NCPE-Summary21.pdf | 2023-03-09 11:31 | 140k |
| Regorafenib-summary-report-2014.pdf | 2023-03-09 11:31 | 186k |
| Regorafenib-summary-report.pdf | 2023-03-09 11:31 | 186k |
| Regorafenib-summary-report1.pdf | 2023-03-09 11:31 | 186k |
| Regorafenib-summary-report2.pdf | 2023-03-09 11:31 | 186k |
| Regorafenib-summary-report3.pdf | 2023-03-09 11:31 | 186k |
| Regorafenib-summary-report4.pdf | 2023-03-09 11:31 | 186k |
| Summary-Report-for-dabrafenib.pdf | 2023-03-09 11:31 | 124k |
| Technical-Summary.pdf | 2023-03-09 11:31 | 124k |
| Trastuzumab-emtansine-summary.pdf | 2023-03-09 11:31 | 100k |